Fichter Andreas M, Ritschl Lucas M, Rau Andrea, Schwarzer Claudia, von Bomhard Achim, Wagenpfeil Stefan, Wolff Klaus-Dietrich, Mücke Thomas
Department of Oral and Maxillofacial Surgery, Technische Universität München, Klinikum rechts der Isar, Munich, 81675, Germany.
Institute for Medical Biometry, Epidemiology and Medical Informatics, Universität des Saarlandes, Homburg, Germany.
J Craniomaxillofac Surg. 2016 Dec;44(12):1889-1895. doi: 10.1016/j.jcms.2016.09.010. Epub 2016 Sep 23.
The warm ischaemia time of microvascular free flaps is limited. Incalculable events, such as lack of adequate recipient vessels or intraoperative medical emergencies, can lead to prolonged ischaemia and potentially to flap loss. In this study, critically perfused ischaemic or congested flaps were temporarily perfused with an extracorporeal perfusion system until anastomosis could be commenced. Temporary extracorporeal perfusion was performed in 8 radial forearm flaps for 147 ± 52 (range 77-237) minutes. Flap perfusion was assessed using Indocyanine Green fluorescence angiography and combined laser Doppler flowmetry and remission spectroscopy. Results were compared with those of 30 patients who underwent conventional reconstruction with radial forearm flaps. Flap survival, flap microcirculation, postoperative complications, and hospital stay did not differ between groups. We report successful free flap transfer after short-term extracorporeal perfusion for up to 4 h in 8 patient cases. Temporary extracorporeal free flap perfusion reduces the warm ischaemia time in emergency situations and can help to prevent flap failure in critically perfused or congested flaps. The trial is registered with ClinicalTrials.gov, number NCT02449525.
游离微血管皮瓣的热缺血时间有限。一些无法预估的情况,如缺乏足够的受区血管或术中医疗紧急情况,可能导致缺血时间延长并有可能导致皮瓣坏死。在本研究中,对严重灌注不良的缺血或充血皮瓣使用体外灌注系统进行临时灌注,直到可以开始吻合。对8例桡侧前臂皮瓣进行了147±52(范围77 - 237)分钟的临时体外灌注。使用吲哚菁绿荧光血管造影以及激光多普勒血流仪和反射光谱联合技术评估皮瓣灌注情况。将结果与30例行常规桡侧前臂皮瓣重建的患者进行比较。两组之间的皮瓣存活情况、皮瓣微循环、术后并发症及住院时间并无差异。我们报告了8例患者在短期体外灌注长达4小时后成功进行游离皮瓣移植的病例。临时体外皮瓣灌注可在紧急情况下缩短热缺血时间,并有助于防止严重灌注不良或充血皮瓣出现皮瓣坏死。该试验已在ClinicalTrials.gov注册,注册号为NCT02449525。